NATCO gets tentative USFDA nod for Ibrutinib tablets

NATCO gets tentative USFDA nod for Ibrutinib tablets

53
Medicine Tablet
Picture: Pixabay

NATCO Pharma is pleased to announce that its marketing and distribution partner Alvogen Pine Brook LLC, has received tentative approval for our Abbreviated New Drug Application (ANDA) for Ibrutinib Tablets 560mg, 420mg, 280mg and 140mg strengths (generic for IMBRUVICA ), from the US Food and Drug Administration (USFDA).


To read more articles on Natco Pharma, click here


“Based on our ANDA filing date and the approval timeline, NATCO believes that we are eligible for 180 days of sole generic marketing exclusivity for all the strengths of the tablet dosage form of the product at the time of launch,” informed a company statement.

FDA

As per industry sales data, IMBRUVICA (Tablet and Capsule dosage forms) had generated annual sales of $3.7 billion during the twelve months period ending December 2020 in the US market, of this, all the strengths of IMBRUVICA Tablets alone generated sales of $3.0 billion during the same period.


Also read:

First AI device to help detect colon cancer gets USFDA nod

Aleor gets tentative USFDA nod for drug for topical treatment

Zydus Cadila gets final USFDA nod for drug to treat High…

Dr Reddy’s launch generic Sapropterin Dihydrochloride Powder for Oral Solution in…

Camber Pharma Launches Generic Succinylcholine Chloride Inj

Aleor gets USFDA nod for drug for cutaneous candidiasis treatment


Enter your email address:

Delivered by FeedBurner

Latest updates

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading